PridCor Builds Antiviral Pipeline Targeting Long COVID, Viral Chronics

PridCor Therapeutics LLC has acquired a global antiviral asset portfolio that positions the Tuscaloosa-based clinical-stage company at the forefront of a therapeutic category with no approved standard of care: infection-associated chronic illness (IACI). For drug development teams and regulatory strategists watching the Long COVID pipeline, the transaction signals that multi-mechanism antiviral combinations are moving from hypothesis to late-stage clinical programs.

The acquired portfolio centers on two candidates. IMC-1 is described as Phase 3-ready for fibromyalgia. IMC-2 is a fixed-dose combination at Phase 2b-ready status, targeting the full symptom spectrum of Long COVID and related conditions including ME/CFS, fibromyalgia, and IBS. Both assets are built around the viral reactivation hypothesis, a mechanism gaining traction across multiple chronic disease research programs.

PridCor is also advancing its proprietary combination antiviral regimen into the SHIELD study at the Icahn School of Medicine at Mount Sinai, building on a recently published Long COVID case series. The collaboration with a major academic medical center adds an independent validation layer to the company's clinical rationale. Supporting research has been published in Frontiers in Immunology.

Dr. William Pridgen, Co-Founder and CEO, stated: "We are building a category-defining company focused on solving one of the largest unmet needs in modern medicine. With a Phase 3-ready asset and a Phase 2b-ready combination therapy, we are uniquely positioned to accelerate clinical development and deliver meaningful solutions to millions of patients who currently have none."

For development and regulatory teams, the pipeline's reliance on fixed-dose combinations and multi-mechanism antiviral agents will require careful attention to CMC strategy, bioequivalence considerations, and the evolving ICH guidance landscape for complex combination products. PridCor is privately held. Source: GlobeNewswire, April 23, 2026.